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Abstract 
 
Gene therapy is an emerging field in regenerative medicine that is finding a definitive 
cure to many diseases rooted on a genetic impairment. On the other hand, Dyskeratosis 
Congenita (DC) is a rare disease caused by a mutation in gene DKC1 coding for one of 
the subunits of the telomerase complex, standing out as a potential candidate for gene 
therapy; however, this possibility has not been studied yet and currently DC is treated 
with conventional treatments. In the present study, transgene GSE4, derived from 
DKC1 gene, was transduced in DC keratinocytes in order to achieve genetic correction. 
This correction was initially surveilled through the expression of reporter GFP gene; 
however, when the GSE4 keratinocytes proliferated significantly, in vitro skin 
equivalents were grown from the corrected cells in order to evaluate their behavior in an 
organotypic culture. The GSE4 correcting transgene achieved a 97% successful 
transduction in the DC keratinocytes, in contrast with preliminary studies that used 
GSE4 precursor but did not achieve a positive transduction. The obtained results proved 
that DC can be targeted at its core through gene therapy, opening the path to further 
research in this direction and giving a new hope to the patients of this rare disease. 
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Introduction 
 
 
Background, Motivation and Goals 
 
Dyskeratosis Congenita (DC) is a rare disease with an extremely heterogeneous 
genotype as well as phenotype, including initial skin disorders which, as the disease 
progresses, degenerate into bone marrow failure and increased cancer predisposition. 
Even though, as a rare disease, not many cases have been reported, most of them end up 
being fatal during the earliest years of life. As a condition with more unknowns than 
equations, its understanding has been delayed by the scientific community for a long 
time.  
It has only been during the last ten years that the reasons behind this rare disease have 
started to be disentangled, and real treatments other than just mere everyday guides for 
good practice have been proposed. However, none of them has targeted Dyskeratosis 
Congenita at its core yet. The disease is rooted on a genetic mutation at the DNA-level 
in one of the subunits of the telomerase complex, dyskerin. 
The present study aims to find a potential cure to DC by directly correcting this genetic 
impairment through gene therapy. Even though such an approach promises to be the 
most definitive cure for this genetic disease, so far no precedents have been reported in 
the literature of Dyskeratosis Congenita. 
 
The goal of this project is to infect DC patient’s epidermal cells with a lentiviral vector 
that contains the therapeutic gene GSE4 as its genetic material. In this gene therapy, 
GSE4 codes for the healthy version of dyskerin gene that will replace the defective 
mutated one in Dyskeratosis Congenita. GSE4 behaves as the equivalent of a drug in 
contemporary medicine, and through this simple genetic switch, DC is expected to 
disappear. 
In order to assess the efficiency of the proposed gene therapy, an in vitro skin model is 
developed using the corrected epidermal cells as the building blocks. The behavior, 
proliferation, and GSE4 expression of the corrected cells, as well as the structure of the 
grown in vitro skin model, are parameters of whether the previously DC cells have been 
indeed genetically converted into healthy ones. 
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Skin 
 
Function 
The skin is the main organ from the integumentary system, which essentially is a 
cutaneous membrane covering the outer surface of the body. Hair, skin glands and nails 
are accessory structures of the skin in the integumentary system [1]. 
The main function of skin is protection. Skin provides the first line of defense against 
external agents trying to invade an organism. However, it additionally carries out 
several other functions: Skin regulates body temperature by sweating and by adjusting 
blood flow to the dermis; it is responsible of sensory perceptions; it synthesizes vitamin 
D; skin carries out excretion of sweat and absorption of gases, and even more functions. 
Regarding the layered structure of skin, the epidermis is responsible of protection and 
resistance against damage, whereas the dermis prevents dehydration, regulates 
temperature, and is involved in healing.  
 
Structure 
Skin is composed of two basic tissues: Epithelial tissue forming the epidermis, and 
connective tissue composing the dermis. In the skin, the epithelial tissue is the 
parenchyma which is supported by a stroma made of connective tissue. 
 
Fig 1: Sectional view of skin and subcutaneous layer [2]. 
 
Epidermis is the uppermost thin layer of skin, consisting of closely packed cells forming 
continuous sheets. Epithelial tissue is always avascular, therefore obtaining all the 
nutrients required for cell survival from the underlying connective tissue found in the 
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dermis. Epithelial tissue always sits on a basement membrane which tightly connects it 
with the dermis. The basement membrane is a thin, highly organized layer of 
Extracellular Matrix mostly composed of collagen IV (lamina densa) and laminin 
(lamina lucida). The dense network in the basement membrane connects to the cells in 
the stratum basale of the epidermis through the interaction between fibronectin and 
cellular integrin. At the same time, the lamina lucida connects to the fibers in the 
connective tissue of the dermis [1].  
In particular, the type of epithelial tissue found in the skin is keratinized stratified 
squamous epithelium, which has an apical surface made up of several layers of 
squamous (flat) cells. This structure with many layers provides protection against strong 
friction forces. The epidermis has four layers in the case of the thin (hairy) skin, and 
five layers in the case of thick (hairless) skin, pictured in Fig 2. 
 
Fig 2: Layers of the epidermis [1]. 
 
i. The stratum basale, adjacent to the dermis, is where new keratinocytes are 
produced by skin stem cells through continuous cell division. It is the only 
mitotically active layer in the epidermis. 
ii. The stratum spinosum is a layer of 8-10 keratinocytes. 
iii. The stratum granulosum contains non-dividing cells filled with keratin granules. 
iv. The stratum lucidum only exists in thick skin. 
v. The stratum corneum is the outermost layer of the epidermis. It is composed of 
around 20 layers of dead keratinocytes filled with keratin that are continuously 
replaced from deeper strata. Keratinization is the process in which keratinocytes 
accumulate increasing amounts of keratin, the skin-specific intermediate 
filaments, as they move upwards to the skin surface. 
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Dermis is the inner, thick layer of skin. The connective tissue in the dermis carries 
blood and lymphatic vessels, as well as nerves [1]. The dermis is divided in two regions: 
i. The papillary region lies just below the epidermis. It is made of areolar CT, a 
type of loose CT, therefore containing mostly ground substance and fibroblasts 
than ECM fibers. The papillary region contains capillary and free nerve endings.  
ii. The reticular region consists of dense irregular CT, which contains an abundant 
extracellular matrix composed of thick collagen and elastic fibers with 
fibroblasts immersed in it. It also contains hair follicles, sebaceous glands and 
sudoriferous glands. 
Fibroblasts are the main residents in the connective tissue. They are extremely versatile 
cells involved in the production of collagen and elastin fibers in the ECM. 
 The subcutaneous layer located underneath the dermis is called hypodermis. However, 
it is not part of the skin. The hypodermis is formed by areolar and adipose CT, and its 
role is to anchor the skin to the underlying tissues and organs. The lamellated (Pacinian) 
corpuscles that detect external pressure applied to the skin are found in the hypodermis.  
 
Epidermal Stem Cells 
The epidermis contains four major cell types, displayed in Fig 3: 
 Keratinocytes: They count up to the 90% of 
the cells found in the epithelial tissue. They 
produce keratin, which is a tough fibrous 
protein essential for protection. 
 Melanocytes: They produce melanin 
pigment, involved in UV protection. 
 Langerhans Cells: Macrophages originated 
in the red bone marrow, carrying out 
immune responses. 
 Merkel Cells: Involved in the sensation of 
touch along with adjacent tactile discs. 
In addition, skin contains stem cells which are found in the epidermis and hair follicle. 
These stem cells are involved in skin renewal, homeostasis and wound healing [3]. The 
main types of skin stem cell are Melanocyte SCs, Hair Follicle SCs, and Epidermal SCs. 
Fig 3: Main cell types in the epidermis [1]. 
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Epidermal SCs are found in the stratum basale of the epidermis and are involved in the 
continuous regeneration of the different layers of the epidermis [4]. In the epidermis, the 
stratum basale contains all the alive cells whereas the stratum corneum contains only 
dead cells. In between, an ascending process of keratinocyte differentiation takes place. 
As epithelial stem cells leave the basal layer and move upwards towards the surface of 
the skin, they quit cellular division, switch off integrin expression and increase keratin 
accumulation. All these processes are part of the terminal differentiation program that 
converts St. Basale epithelial SCs into St. Corneum dead differentiated keratinocytes. 
Among other signaling factors, the main promoter of keratinocyte differentiation is 
calcium gradient. In the epidermis, the lowest calcium concentration is found at the 
stratum basale, whereas at the stratum corneum this concentration is very high. A reason 
for this singularity is that dead keratinocytes are not able to dissolve calcium ions [5]. 
High levels of extracellular Ca induce an increase in intracellular Ca ions in the 
keratinocytes. On the other hand, vitamin D3 (cholecalciferol) ultimately regulates the 
expression of those genes involved in keratinocyte differentiation depending on the 
levels of intracellular calcium [6]. A general diagram of the different factors involved in 
epithelial stem cell differentiation is shown in Fig 4 below: 
 
Fig 4: Epidermal Stem Cell differentiation along the section of the epidermis. 
 
In the present study we will work with primary keratinocytes and with epidermal stem 
cells, which have the ability to continuously divide and the potentiality to terminally 
differentiate in keratinocytes. However, in general terms, they will be simply called 
keratinocytes along the study.  
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Dyskeratosis Congenita 
 
Phenotype 
Dyskeratosis Congenita (DC) is a rare congenital disease of multisystem characteristics. 
It was first described by Zinsser in “Atrophia cutis reticularis cum pigmentatione, 
dystrophia unguium et leukoplakia oris” in 1906, and recognized as a clinical entity by 
Engman (1928) and Cole (1930) [7], from whom it obtained the alternative name of 
Zinsser-Cole-Engman syndrome. The estimated annual incidence of DC is <1 in 1 
million, and 30 cases have been diagnosed so far in Spain [8]. 
DC has a highly variable phenotype. The main distinguishing symptoms of DC typically 
are skin pigmentation, nail dystrophy and oral leukoplakia, the three of them shown in 
Fig 5. However, many other characteristics have been observed in DC patients, such as 
mental retardation, conjunctivitis or pulmonary complications. In spite of this, neither 
do these symptoms appear at the same time nor to all patients: the phenotype in DC is 
extensively wide, heterogeneous and systemic [9].  
 
Fig 5: Main phenotypic features of DC: (A) Skin pigmentation. (B) Oral leukoplakia. (C) Nail distrophy. [10] 
Although initially the most affected organ is skin, as the disease advances a progressive 
bone marrow failure appears in 80% of the patients.  This condition is a major cause of 
mortality in DC patients, being most of the deaths caused by opportunistic infections 
enhanced by a deficiency in the hematopoietic stem cells found in the bone marrow. In 
addition, DC patients suffer an increased risk of malignancy which typically develops in 
the third decade of life. Squamous cell carcinoma within sites of leukoplakia as well as 
in the skin is the most common form of malignancy found in DC patients, although 
hematolymphoid neoplasms have also been observed [11]. 
Finally, DC includes a variety of many minor features due to its multisystem character, 
such as developmental delay, microcephaly or premature aging, among others.  In 
conclusion, dyskeratosis congenita contains many disorders within the same disease: 
DC can be seen as a hematological disease due to BMF; it can be seen as an aging 
disorder, but also as a developmental disorder; DC is a cancer syndrome and an oral 
condition. And the list keeps increasing as the disease is further understood.  
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Nevertheless, from the highly heterogeneous phenotype in Dyskeratosis Congenita, in 
the present study we will only focus on the epithelial manifestations of the disease. 
 
Fig 6: A model of dyskeratosis congenita pathophisiology [10]. The main phenotype features of the disease are 
highlighted: Initially at birth, nail distrophy, oral leukoplakia and skin pigmentation are the most common 
manifestations of the disease. However, bone marrow failure and enhanced cancer predisposition become the main 
manifestations of DC at the age of 30 years. 
 
Causes 
Dyskeratosis Congenita is a telomeropathy, meaning that a defective telomerase is the 
ultimate responsible of the disease [12]. The reasons behind this telomerase defect are 
genetic: one or more mutations in the long arm of the X chromosome at gene DKC1, 
codifying for one of the protein subunits of the telomerase, have been shown to cause 
the disorder. 
Telomere is the name given to the region of repetitive sequences of nucleotides found at 
each end of a chromosome, whose role is genetic protection. During each DNA 
replication, the chromosomal ends are shortened due to an impairment of the cellular 
replication machinery. The function of the telomere is to behave as protective caps at 
the ends of the chromosomes, by avoiding the deterioration of the indeed codifying 
genes found at the interior of the chromosome by getting themselves shortened instead. 
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As a consequence, telomere shortening is a cumulative process strongly linked with 
aging. The role of telomerase complex is to fix this. 
The telomerase enzyme performs telomere elongation by adding a sequence of 
repetitive nucleotides to a shortened telomere in order to counteract the above described 
effect. It carries a RNA molecule which is used as a template during reverse 
transcription [13].  
Each telomerase is a ribonucleoprotein complex made of two main subunits (Fig 7): the 
telomerase RNA component (TERC) and the telomerase reverse transcriptase (TERT). 
TERT is the catalytic subunit, which by reverse transcription produces single-stranded 
DNA from the template RNA at TERC. Although a functional telomerase is composed 
of TERT and TERC, additional proteins are found in the complex, such as dyskerin in 
the case of vertebrates, which stabilizes the telomere complex [14]. 
 
Fig 7: Structure of the telomerase complex and diseases associated with mutations in the complex subunits. 
Mutations in TERT, hRT (TERC) and Dyskerin lead to dyskeratosis congenita. [15] 
 
The genes codifying for the different telomerase subunits are located on different 
chromosomes. In particular, H/ACA ribonucleoprotein complex subunit 4 or dyskerin is 
encoded by gene DKC1 in humans, located at chromosome X [16]. Dyskeratosis 
congenita is mainly caused in a 35% of the cases by an X-linked recessive DKC1 
mutation, whereas a 5% of the cases the mutation takes place at TERT and TERC loci. 
The disease has been found to have a significantly higher incidence in males due to its 
location at the X-chromosome, whereas women are often recessive female carriers [17]. 
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In the present study we will focus on the predominant X-linked recessive Dyskeratosis 
Congenita caused by a mutation in gene DKC1 (Fig 8). 
 
Fig 8: Mutations in the DKC1 gene, developing dyskeratosis congenita. Three splicing mutations and one 
promoter mutation have been found in DC patients. [18] 
 
In vitro DC cells exhibit short telomeres and defective telomerase activity. Typically, 
telomerases are active in the early stages of life whereas becoming inactive in adult 
somatic cells [19], except in rapidly dividing cells such as those that line the lungs, skin 
cells or cells in the bone marrow [20]. As a result, since Dyskeratosis congenita patients 
have inactive telomerases since their birth, chromosomal instability, stem cell depletion, 
tissue failure and premature aging become a major risk earlier than expected in healthy 
individuals [21]. Furthermore, it is important to highlight that those tissues formed by 
rapidly dividing cells become the most damaged under DC; since replication is 
particularly frequent in these cells, telomere shortening is accelerated and telomerase 
function becomes more critical. The main manifestations in DC, such as skin disorders 
or BMF, illustrate the burden of these rapidly dividing tissues. 
However, the origin of DC is not merely genetic. Two DC patients with a mutation in 
the same gene can have different manifestations of the disease. Genotype-phenoype 
relation is complex, and it is strongly influenced by underlying hypomorphic gene 
mutations, and genetic and environmental modifier effects [22]. 
 
Treatment 
Up to the present moment, no cure for Dyskeratosis congenita has been officially found 
yet. In fact the disease has only been studied during the last fifteen years. However, 
since the phenotypes of the patients are so heterogeneous in terms of clinical features 
and seriousness, the scientific community has not reached a consensus about how to 
efficiently treat the patients of this rare disease [23]. So far, a variety of treatments 
directed to the different specific symptoms of the disease have been applied. 
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The general treatment indications currently given to DC patients are usually rather a 
guide for good practices than a real therapy: smoking and alcohol are avoided in order 
to preserve the liver and the lungs, moisturizing creams are commonly used to prevent 
skin damage and good dental hygiene is recommended to prevent early tooth loss. 
Androgens and hematopoietic growth hormones have been used as short-term therapies 
for the BMF and immunodeficiency characteristics of the disease. Androgens such as 
oxymetholone have eventually shown to increase red blood cells production, and to 
reduce bleeding associated with thrombocytopenia when combined with corticosteroids 
[24]. This result might be explained by the observed telomerase modulation under the 
effects of sex hormones [21]. On the other hand, hematopoietic growth factors such as 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-
stimulating factor (G-CSF) have transiently increased neutrophil population in patients 
with BMF [25]. However, both therapies should under no circumstances be adopted 
together, under a risk of splenic peliosis and rupture [26]. 
The only currently accepted long-term therapy for BMF in DC is allogeneic 
hematopoietic stem cell transplantation, which would replace the defective DC stem 
cells with the healthy donor’s ones [27]. This therapy would potentially cure the 
complications associated with bone marrow failure, but would not improve the rest of 
the tissues already affected by DC. In spite of the promising perspectives of 
hematopoietic SCT as a potential therapy, immunogenicity and graft-versus-host-
disease, as in any other cell therapy, are two limiting factors to be considered [28]. 
Twenty-one myeloablative procedures have been so far reported by the literature; 
nevertheless, none of them has been considered to be successful due to the pulmonary 
complications observed after myeloablative hematopoietic SCT transplantation. On 
contrast, recent non-myeloablative conditioning protocols (i.e, reduced-intensity 
conditioning) have yielded successful engraftment [29]. DC patients have been reported 
to be extremely sensitive to myeloablation and radiation, and a recent non-
myeloablative approach has shown a 22% mortality rate versus a 71% mortality rate 
with traditional myeloablative procedures [30].  
Finally, genetic analysis might be crucial in the future for an early diagnosis of the 
disease. Early harvest and storage of their bone marrow could be then performed in 
order to be used as an immunocompatible autotransplant after anticipated marrow 
failure [31]. 
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Gene Therapy 
 
Mechanism 
Gene therapy is a novel therapy belonging to future medicine, which aims to cure 
genetic diseases by genome manipulation. Compared with traditional therapies, gene 
therapy approaches medicine from a new perspective that has not been fully exploited 
yet: genetics. As a medicine of the future, it is expected to be personalized and 
preventive and will be a way to fix genetic diseases at their root. 
The fundamentals of gene therapy consist on delivering DNA sequences in the cell as a 
drug, with the purpose of fighting a disease by allowing target cell identification and/or 
expression of the protein of interest. The DNA modification can include gene insertion, 
deletion, or replacement by another gene. Gene therapy can be classified into germline 
gene therapy (GGT), in which the genetic modification is heritable to subsequent 
generations, or somatic cell gene therapy (SCGT), in which it is not and the therapy 
results are only restricted to the actual patient. So far GGT remains controversial due to 
its ethical consequences, and research has only been carried out on SCGT [32]. At the 
same time, SCGT can be divided into ex vivo gene therapy, in which the cells are 
corrected outside the patient’s body and then injected back (Fig 9), and in vivo gene 
therapy, in which genetic correction happens inside the patient’s body. 
 
Fig 9: Steps involved in ex vivo/in vitro gene therapy, in which the cells are genetically modified outside the 
patient's body [33]. 
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The engineered gene construct or transgene containing the DNA sequence of interest to 
be delivered can be designed by using different genome editing tools known as 
engineered nucleases. Traditionally, the restrictions enzymes or endonucleases naturally 
found in the cells such as EcoRI or BamHI were used. Lately, more specific and direct 
techniques such as Transcription-activator like effector nucleases (TALENs) or Zinc 
finger nucleases (ZFNs) have been developed in order to avoid multiple double strand 
breaks [34]. Nevertheless, the real breakthrough in genetic engineering came in the last 
four years with CRISPR/Cas9. This enzymatic complex naturally found in the 
prokaryotic immune system promises to be the fastest, simplest, cheapest, and most 
importantly, most precise and specific tool for customized genetic engineering. 
CRISPR/Cas9 is revolutionizing the world of genetic engineering and synthetic biology, 
and it was the winner of Science Magazine’s Breakthrough of the Year award in 2015 
[35]. DNA delivery is accomplished by vectors, which will be described in the next 
section. 
 
Vectors 
Vectors are the carriers of the genetic material that will be used as a drug in gene 
therapy. The most widely used vectors in gene therapy are viruses, although recently 
research on non-viral vectors is being carried out since they allow simpler large scale 
production and low host immunogenicity. Injection of naked DNA, electroporation, and 
nanoparticles such as lipoplexes, polyplexes or gold nanoparticles are some of the non-
viral gene therapy vectors that have been studied [36]. 
On the other hand, throughout evolution viruses have naturally developed a way to 
infect human beings and efficiently discharge their genetic material in the host cell. 
Gene therapy takes advantage of this simple natural vector as the most effective way to 
introduce DNA in a human cell. The construction of safe viral vectors is guided in 
packaging cells, in such a way that the disease-causing genes are replaced by the 
therapeutic ones. 
Adenovirus, adeno-associated virus, and retrovirus have already been used in gene 
therapy clinical trials, being the last ones the most common scaffold in vector 
engineering. The genetic material in retroviruses appears in its RNA form; therefore it 
must undergo reverse transcription upon integration in the host’s DNA. This procedure 
is carried out by reverse transcriptase and integrase respectively, two enzymes encoded 
by polymerase (pol). In general, every retrovirus requires three essential proteins that 
make it functional: not only the previous described pol gene, but also, from a structural 
approach, group-specific antigen (gag) coding for the retroviral core proteins and 
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envelope (env) coding for the viral coat proteins. However, for safety reasons, in gene 
therapy the retroviruses never carry these three genes required for their replication and 
survival and their empty space is filled with the transgene. Gene therapy retroviruses are 
produced in packaging cells, typically HEK 293T cell line, transfected with different 
packaging plasmids containing gag/pol, env, rev for regulation and the transgene trans 
of interest (Fig 10). Through this procedure, the enzymes required for building up the 
virus are externally produced, whereas the transgene becomes the new genetic material 
in the retrovirus. Upon integration in the host’s genome, the engineered gene will be 
inserted but not the viral promoters, so there will be no viral proliferation. 
 
Fig 10: Production of retroviral vectors in packaging cells [34]. 
 
Lentiviruses and γ-retroviruses are the most common gene therapy vectors used from 
the retrovidae family. However, their main drawback is that integration in the patient’s 
genome is arbitrary: gene disruption and activation of proto-oncogenes are important 
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factors of risks when using these vectors. In particular, lentiviruses are interesting 
vectors in gene therapy because they can integrate into the genome of non-dividing cells, 
such as in the case of keratinocytes, which cycle significantly slowly [37]; moreover, 
recent studies have shown that lentiviruses have lower tendency to induce cancer than 
other vectors [38]. HIV-1 (human immunodeficiency virus 1), represented in Fig 11, is 
the most common lentiviral vector. 
 
Fig 11: Scheme of lentiviral genome of HIV-1. In gene therapy, the coloured viral sequences tat, rev, gag, pro, pol, 
nef, vif, vpr and vpu are replaced by the therapeutic transgene. 
 
In the present study, ex vivo / in vitro gene therapy will be carried out using modified 
HIV-1 lentivirus as the gene GSE4 (derived from DKC1 gene) delivery vectors. 
 
History and State-of-the-art 
The first evidences of gene therapy appeared in 1969 when a research group from 
Tenesse achieved arginase proficiency in arginase deficient animals and humans 
through Shope papilloma virus infection [39]. The first attempt at modifying human 
genome dates back to 1980, although the first successful human gene transfer was 
performed in 1989 [40]. One year after, the first approved clinical research took place in 
the National Institute of Health in the United States, under the direction of William 
French Anderson. The results obtained from that primitive gene therapy were temporary, 
but successful [41].  
Even since then, 2200 clinical trials [42] have been conducted and huge technological 
advances have taken place in the field of gene therapy. The therapy has been applied to 
most of the organs in the human body: for instance, in 2003 genes were inserted into 
brain for the first time [43]. Currently, a gene therapy product for Fanconi Anemia 
treatment is being developed at phase I/II by a research group from CIEMAT [44]. The 
highest breakthroughs have taken place in the last five years, during which several drugs 
based on novel gene therapy have been approved: Gendicine in China in 2003 [45], 
Neovasculgen for peripheral artery disease in Russia in 2011 [46], Glybera for 
pancreatitis in 2012 [47] or Strimvelis for ADA-SCID disease in “bubble-babys” in 
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April 2016 [48]; Glybera and Strimvelis are the only two gene therapy treatments 
approved so far in Europe. 
On the other hand, a paradigm shift in gene therapy has arisen in the last years with of 
CRISPR/Cas9. Its recent presentation as a new way of specifically editing the genome 
offers a new promising approach to gene therapy. 
In conclusion, even though gene therapy is still in its infancy, it is already stablishing 
itself as the medicine of the future. Nevertheless, the technology still has some 
challenges to overcome: the current methods of gene therapy are short lived and would 
require of multiple rounds of treatment; also, gene therapies for multigene disorders 
such as Alzheimer’s disease or diabetes still have to be developed. However, the 
greatest challenges are still the immunogenic and tumorigenic risks posed by the current 
viral vectors.  
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Skin Bioengineering 
 
Fibrin Scaffold 
Regenerative Medicine aims to stimulate the body’s intrinsic regenerative capacity, 
mainly through the activity of stem cells. Tissue Engineering studies the strategies to 
artificially create tissues and organs. And, both of them, Tissue Engineering and 
Regenerative Medicine (TERM), are 
emerging fields also belonging to the 
previously described medicine of the 
future. The classical paradigm in 
tissue engineering consists of three 
main elements: a biocompatible 
scaffold of the tissue of interest, the 
cells that will seed this scaffold, and 
the signaling molecules allowing the 
similar to in vivo behavior of these 
cells in the scaffold [49]. 
 
When tissue engineering focuses on developing artificial skin, the result is skin 
bioengineering. Hydrogel scaffolds have proved to be the most useful ones in skin 
bioengineering due to their soft tissue ECM-like stiffness and their capacity of 
controlled release of signaling molecules and nutrient diffusion [50], and in particular 
fibrin hydrogel scaffolds (World Patent WO/2002/072800) [51]. Fibrin hydrogels 
resemble the mechanisms of wound healing to induce in vitro skin growth just like it 
would naturally take place in our bodies [52]:  
i. Blood clotting: Platelets aggregate into a platelet plug, then they activate and 
release clotting factors that will initiate the coagulation cascade (Fig 13) and 
ultimately end with the synthesis of fibrin. Under the presence of calcium ion 
found in plasma, thrombin produces fibrinogen, a precursor of fibrin. 
ii. Formation of a stabilizing matrix of fibrin that behaves as a temporary ECM and 
enhances cell adhesion and platelet activation. 
iii. Remodeling: Fibroblasts migrate to the wound site and contract the skin gap by 
proliferation, creating a scab. Finally, fibroblasts secrete collagen that gradually 
replaces the temporary fibrin matrix by permanent collagen ECM. At the same 
time, epithelization takes place and the stratified skin structure is formed.  
Fig 12: The three main elements in the classical paradigm of 
tissue engineering [49]. 
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In skin bioengineering, the fibrin hydrogel is formed in vitro by artificially mimicking 
the above described wound healing cascade, as represented in Fig 13. Plasma thrombin, 
fibrinogen and CaCl2 are mixed and the fibrin matrix is spontaneously formed just as it 
would under the existence of a wound. On the other hand, and based on the tissue 
engineering strategy shown in Fig 12, the building blocks in skin bioengineering are 
keratinocytes and fibroblasts, which are seeded in the fibrin clot [53].  
 
Fig 13: Comparison between the in vivo wound healing mechanism and the mimicking in vitro fibrin gelation 
mechanism for skin bioengineering. 
 
Skin Equivalent Development 
The third and final element in tissue engineering is the signaling molecules. Upon 
receiving the signaling factors released from the fibrin matrix, fibroblasts will 
understand that it is a wound and they will release collagen, which will ultimately form 
the final, mature ECM matrix. This part of the hydrogel would resemble the skin dermis. 
Above the in vitro dermis, the epidermis is created from keratinocytes and epidermal 
stem cells, which are initially seeded into a cellular monolayer. However, the calcium 
gradient in the keratinocytes media also serves as a signaling factor during this process 
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of epithelization, in which the keratinocytes are exposed to an air-liquid interface 
resembling the apical and basal epidermal surfaces respectively, thus inducing terminal 
epidermal differentiation and stratification into a mature epidermis [54]. The final 
structure of the skin equivalent is displayed in Fig 14: 
 
 
Fig 14: Fibrin-based Skin Equivalent structure [51]. (A) Schematic of a skin equivalent in a cell culture with a 
PET membrane (1 µm pores). The surface keratinocytes are exposed to air, whereas the matrix is few by medium 
from below. (B) Skin equivalent after incubation for 17 days at the air/liquid interface showing an intact and dry 
surface of stratum corneum, indicating successful epidermal stratification. 
 
In the present study, a bioengineered skin equivalent will be created from Dyskeratosis 
congenita keratinocytes corrected by gene therapy. 
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State-Of-The-Art  
 
Dyskeratosis Congenita is a disease that has not been understood until the most recent 
fifteen years, and that has not been targeted at its root by any therapy yet. Due to its 
genetic origin, gene therapy would be the most logical treatment for such a disorder; 
nevertheless, no projects on gene therapy for Dyskeratosis congenita have been reported 
in the literature [55]. In the present section, the most recent approaches of regenerative 
medicine in DC and the models of the disease will be analyzed. In addition, the studies 
from which the present gene therapy project is based on will be described. 
 
In vitro DC models 
Lately, several groups have tried to model Dyskeratosis congenita in mice with varying 
success [56]. One of the earliest mice models was carried out by Ruggero et al in 2003: 
they developed a line of DKC1 mice and reproduced many features of DC in the model, 
such as reduced telomere length, increased predisposition to cancer, and decreased 
cellularity in the bone marrow. However, their model reported additional peculiarities 
that had not been observed in DC patients [57]. In 2008, Hockemeyer et al reproduced 
hyper pigmentation of the skin, bone marrow failure and nail dystrophy in their mice 
model; however, their model was developed from the mutation in a gene that does not 
exist in human DC [58]. In general, the problem with the developed mice models is that 
none of them provides a faithful replication of human DC due to its highly variable 
phenotype. 
In 2010, Agarwal et al. published an article in Nature that has created high expectations 
in DC modelling among the scientific community. The project, carried out by research 
groups from Harvard University, the National University of Singapore and Nankai 
University in China between others, studied the disease in induced Pluripotent Stem 
Cells (iPSCs) from DC patients [59]. Recalling that DC is caused by a defect in human 
telomerase, and considering that telomerase is always active in those continuously 
dividing cells, the group studied whether reprogramming somatic DC cells into iPSCs 
would restore telomerase limitations. The results showed that reprogramming did 
indeed restore telomere elongation and self-renewal; however, upon differentiation of 
the DC iPSCs, telomere length decreased back to the original pathological low levels. 
This indicated that DC cell reprogramming would be useful for studying in vitro the 
mechanisms of the disease, but not for curing it at the somatic level. 
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Characterization of DC keratinocytes 
On the same year 2010, a study stablishing the phenotypic differences between DC 
fibroblasts and DC keratinocytes was published by Gourronc et al. This group studied 
how in DC patients, both fibroblasts and keratinocytes exhibited short telomeres and 
proliferative defects and how the exogenous expression of the TERC component of the 
telomerase in these cells would reverse these defects in keratinocytes but not in 
fibroblasts. [60] This result relies on the natural difference in telomerase regulation in 
healthy cells: under normal, healthy conditions, keratinocytes have some active 
telomerase whereas telomerase in fibroblasts is not detectable [61]. Therefore, the 
exogenous expression of TERC would return the DC keratinocytes to their healthy state: 
some telomerase activity in keratinocytes but none in fibroblasts. This study carried out 
by Gourronc et al. shows how in the epidermal manifestations of DC, the significantly 
affected tissue is only the epidermis, not the dermis. Based on this study, in the present 
project only DC keratinocytes will be corrected by gene therapy. 
 
GSE4 
Once all the fundamentals on the basis and on the therapy that will be studied in the 
present project have been reviewed, it is important to recapitulate on what the present 
research aims to achieve: In this study, X-linked recessive DC keratinocytes will be 
transduced with HIV-1 lentiviral vectors in order to correct the defect in dyskerin 
through gene therapy. The last element to describe in this strategy is the transgene that 
will be delivered as a drug by the lentiviruses: gene GSE4, a recently discovered short 
dyskerin-related peptide. 
 
The first outlines of GSE4 date back to 2008, when a research group from CSIC 
research center in Spain discovered its precursor, GSE24-2 during a screening for 
cisplatin resistance during chemotherapy [62]. GSE24-2 was the name given to the 55 
amino acids-long genetic suppressor element (GSE) belonging to the pseudouridine 
synthase domain (TRUB) in DKC1 gene. GSE24-4 was found to induce impaired 
telomerase inhibition into those cells that had been exposed to chemotherapy or 
telomerase inhibition – meaning that these cells recovered a high telomerase activity. In 
addition, the study discovered that the promoter of the hTERT telomerase component 
was constitutively activated in GSE24-2 cells, meaning that telomerase was indeed 
activated under the expression of GSE24-2. This study was the first one in suggesting 
that expression of the dyskerin motif GSE24-2 induced the recovery of telomerase 
activity and prevented premature senescence in DC cells in a dominant manner. 
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Four years later, the same research group, in collaboration with scientists from The 
Children’s Hospital of Philadelphia, published a second article in which they further 
studied the effects of GSE24.2, either in the form of cDNA or as a peptide, on an X-DC 
mouse line [63]. The two forms, both produced in bacteria and chemically synthesized, 
appeared to reduce the pathogenic effects of DKC1 deficiency. In addition, the study 
revealed that point mutations in two highly-conserved GSE24.2 residues, known to be 
involved in the pseudouridine-synthase activity of dyskerin reversed the therapeutic 
effects of GSE24.2. 
Ever since then, GSE24.2 has been patented by the research group (EP 1947175 A1); 
the European Medicines Agency has approved GSE24.2 as an orphan drug for DC 
treatment (EU/3/12/1070-EMA/OD/136/11); and a genetically customized antiaging 
cosmetic cream based on GSE24.2 peptide has been commercialized by Advanced 
Medical Projects® in collaboration with the University of California [64]. 
 
At the end of 2015, the same research group from CSIC along with further collaborators 
isolated a new shorter peptide derived from GSE24.2: GSE4. GSE4 is an eleven amino 
acids long peptide that exhibits the same therapeutic properties as its precursor; namely, 
increased telomerase activity, reduced cell senescence or activation of hTERT promoter 
[65]. The interesting feature of GSE4 is that its shorter size presents some additional 
value over previous GSE24.2: the chemical synthesis would have a lower cost, cellular 
delivery would be easier, and manipulation and development of variants would also be 
easier. The role of the present project is to perform the next logical step in the study of 
GSE4 in DC patients after the publication of this paper: studying the in vitro 
development of cells expressing GSE4. 
 
GSE4 corresponds to the N-terminal region of GSE24.2, which was partially degraded 
into smaller peptides by mass spectrometry. GSE4 fragment was cloned from the 
GSE24.2 plasmid using PstI and BamHI restriction sites into the final plasmid pRRL-
CMV-GSE4-IRES-eGFP. 
In the present study, this pRRL-CMV-GSE4-IRES-eGFP plasmid (Fig 15 A) will be the 
engineered genetic material in a HIV-1 lentiviral vector (Fig 15 B). Plasmid pRRL is 
characterized for having adjacent U3 and R regions [66]. Since the lentiviruses are 
synthesized in packaging cells, the final vector does not include the gag, pol and rev 
regions present in Wild Type lentivirus. From a general framework, the transgene 
GSE4-IRES-eGFP is limited at the ends by Long Terminal Repeats (LTR) regions. 
LTRs allow the lentivirus to insert its genetic material into the host genome. The 
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expression of the gene of interest is regulated by CMV, the promoter of 
cytomegalovirus. The incorporation of an Internal Ribosome Entry Site (IRES) 
sequence allows the coexpression of two coding sequences under the same promoter; in 
our case, IRES allowed the simultaneous expression of DC and GFP gene under CMV 
promoter [67]. After the transgene there is a wPRE post-transcriptional regulatory 
sequence.  
 
 
Fig 15: Structure of the GSE4 fragments that will be used in the present study [65]. (A) Plasmid pRRL-CMV-
GSE4-IRES-eGFP that will transfect the packaging cells for creating the vector. (B) Lentiviral vector LV CMV-
GSE4-IRES-eGFP that will transduce the DC keratinocytes during gene therapy.  
  
(A 
(B 
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Materials and Methods 
 
The experimental procedure followed during the present project could be divided into 
three consecutive stages, each of them focusing on a different technique, but the three of 
them having a common ultimate goal: in vitro gene therapy. The diagram below 
represents a global overview of the experimental procedure: 
 
Fig 16: Schematic overview of the steps followed in the present experimental procedure of in vitro gene therapy. 
 
The main cells used in the experimental procedure were primary keratinocytes 
(epidermal stem cells) obtained through skin biopsy from patients suffering from DC as 
well as healthy patients. Skin biopsy was obtained from patients after approval from the 
Ethics Committee of the collaborator hospital upon informed consent. The 
distinguishing feature of study in the present project was Dyskeratosis Congenita; 
therefore, the variable groups along the experimental procedure were: 
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  Lentiviral Infection 
K
er
a
ti
n
o
cy
te
s  
Control 
(GFP) 
Transduced 
(GSE4) 
DC patient 
#64 #64 
#157 #157 
Control (Healthy) Healthy patient 
 
Table 1: Groups of study in the present experiment. 
 
1. Gene Therapy:  
 Aim: To genetically correct Dyskeratosis Congenita keratinocytes.  
 Description: The lentiviruses that would work as vectors in gene therapy 
were prepared in packaging cells. These lentiviruses contained the GSE4 
gene that would be inserted into the target keratinocytes upon their 
infection. 
 Location: Bioengineering laboratories (UC3M). 
2. In vitro Skin: 
 Aim: To culture a skin equivalent using the corrected keratinocytes. 
 Description: The previously transduced keratinocytes were co-cultured 
with fibroblasts in a 3D fibrin hydrogel. The 3D co-culture self-
organized into real skin structure, which is divided into layers.  
 Location: Bioengineering laboratories (UC3M). 
3. Histology: 
 Aim: To process the in vitro grown skin into histological slides in order 
to assess them using optical microscopy. 
 Description: The different grown skin models underwent formaldehyde 
fixation, ethanol dehydration and paraffin embedding before being 
sectioned using rotary and cryostat microtomes. Then, H&E staining 
allowed distinguishing the modelled skin structure. 
 Location: Histology Laboratory (CIEMAT). 
The above outlined experimental stages will be next in detail described. 
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1. Lentiviral Transduction of Keratinocytes (Gene Therapy) 
 
Cell culture. 
293T [human embryonic kidney, (ATCC)] cells was the cell line used as packaging 
cells for the lentivirus. Six p100 dishes (Fisher Scientific) were prepared, each of them 
containing 2 million of 293T cells. DMEM [Dulbecco’s Modified Eagle Medium, 
(Fisher Scientific)], which had 10% of inactivated Fetal Bovine Serum [FBS, (Fisher 
Scientific)] and 1% of antibiotic (Penicillin-Stretomycin), was used for 293T cell 
culture. However, prior to transduction, 293T cells were cultured with inactivated 
keratinocytes medium (Kci) in order to ensure compatibility with the target cells. 
Along the whole experimental procedure, all the keratinocytes from the three patients 
previously described were cultured using specific keratinocytes medium (Kca). Kca was 
made of Dulbecco´s modified Eagle medium containing Ham's F12 medium [F12 Nut 
Mix 1X + Glutamax (GIBCO®)], 10% fetal bovine serum, 1.3 ng/ml of triiodothyronine 
[T3, (Sigma Aldrich)], 5 mg/ml of insulin (BioWhittaker), 10 ng/ml of epidermal 
growth factor (EGF), 24 mg/ml of adenine (Sigma Aldrich), 0.4 mg/ml hydrocortisone 
(Sigma Aldrich), 8 ng/ml cholera enterotoxin and antibiotic/antimycotic 1% 
Keratinocyte Serum Free Medium (GIBCO®). However, during transduction inactivated 
keratinocytes medium (Kci) was used in order not to repress viral activity. The 
keratinocytes were cultured over a layer of feeder cells (ATCC), which are 
metabolically active but mitotically inactive irradiated fibroblasts. During the 
experimental procedure #157 keratinocytes reached confluence, and the cell culture was 
subcultured. 
 
Lentivirus production. 
293T packaging cells produce non-replicative lentivirus vectors. The different elements 
composing the virus capsule and polymerization machinery were added to 293T cells 
along with the transgene of interest. Chloroquine (Sigma Aldrich), which worked as a 
membrane permeabilizer, was also added. The exact viral components to add were: 
 Gene gag-pol for the reverse transcriptase: 5 µg. 
 Gene rev for the regulatory proteins: 2,5 µg. 
 Gene env for the viral envelope: 2,25 µg. 
 Gene trans (GFP and GSE4-IRES-eGFP): 9 µg.  
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The composition of gene trans varied depending on the group that the viral vector to 
construct would infect. As shown in Table 1, there were two different groups in 
lentiviral infection: the GSE4-IRES-eGFP transgene would be used for transduced 
groups, whereas GFP transgene would be used for control groups. In both cases, the 
pRRL plasmids containing the transgene were kindly provided by Dra. Perona. As an 
illustration of the composition of the engineered plasmids, the control transgene is 
represented in Fig 17, whereas the GSE4 + GFP transgene was already introduced in 
Fig 15. This control transgene included uniquely the Green Fluorescence Protein gene, 
which only worked as a reporter and did not have any therapeutic function.  
 
Fig 17: Schematic composition of the control transgene [65]. (A) GFP control plasmid. (B) GFP control LV vector. 
 
Transduction. 
In order to carry out viral infection, 3,5 mL of the inactivated media containing the 
293T packaging cells along with the viral vectors in the supernatant were added to the 
corresponding target dish, either GSE4 groups or control groups. This media was 
filtered using 0,2 µm PuraDisc filters (Fisher Scientific), so that 293T cells were not 
added to the keratinocytes culture. Finally, Polybrene [hexadimethrine bromide, (Sigma 
Aldrich)] was used as a transduction enhancer. 1 µL of Polybrene was added per 1 mL 
of viral media, so in total 3,5 µL were added to each keratinocytes culture. The cell 
B) 
A) 
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cultures were incubated at 37 ºC during 6 hours, after which medium was changed and 
incubation at 37ºC continued. One day after the first viral infection, which could be 
assessed under blue-light microscopy (BX53 Olimpus) for detecting fluorescence in the 
keratinocytes culture, the procedure was repeated using a different plasmid 
concentration. 
Transduced keratinocytes were selected, isolated and subcultured in 75 mL T-flasks 
(Thermo Fisher) containing 2 million feeder cells and 15 mL of activated keratinocytes 
medium each. This time Kca was used because viral activity was no more of interest. 
For three weeks, the cell cultures were allowed to grow. Then, cell sorting was applied 
to the GSE4 transduced cells on a Cell Sorter (BD Influx
TM
) which carried out a 
complete selection of these cell cultures based on their fluorescence characteristics. The 
remaining sorted cells were again subcultured and allowed for further amplification, this 
time with assured 100% transduction. On the other hand, during this extended period of 
time, control samples had been kept frozen to guarantee their viability.  
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2. 3D Co-culture for the Construction of a Bioengineered Corrected 
Skin Equivalent (In Vitro Skin) 
 
Fibrin Scaffold. 
The bioengineered skin equivalents would be grown following tissue engineering 
strategy (Fig 12): the previously transduced keratinocytes would be seeded in a scaffold. 
The used scaffold was a hydrogel initially composed of fibrin, mimicking the natural 
skin extracellular matrix. The fibrin in the scaffold would gradually be substituted by 
collagen fibers, naturally secreted by the fibroblasts which would also be embedded in 
the grafts. 
The different cellular elements required for the construction of the fibrin matrix, which 
had been kept frozen to guarantee their prolonged viability –except for sorted 
transduced #157 keratinocytes-, were unfrozen and cultured in T75 flasks. During the 
unfreezing procedure, the cells, the freezing media (1 mL) and 4 mL of DMEM10 were 
mixed and then centrifuged for 10 minutes. Then, supernatant was removed by vacuum, 
thus getting rid of the harmful freezing media which is toxic in liquid conditions. The 
final compositions of the four different T75 culture flasks are shown in Table 2: 
T75 Flask 1 2 3 4 
Skin cells 
2 ml Healthy 
Fibroblasts 
2 ml #157 
Fibroblasts 
2 ml Healthy 
Keratinocytes 
2 ml Control #157 
Keratinocytes 
Feeder 0 ml Feeder 0 ml Feeder 2 ml Feeder (2M) 2 ml Feeder (2M) 
Media 12 ml DMEM10 12 ml DMEM10 10 ml Kca 10 ml Kca 
 
Table 2: Composition of the T75 culture flasks after unfreezing the samples, which would be later used for the 
fibrin scaffold. 
 
On the other hand, the previous feeder cells from the GSE4 #157 keratinocytes culture 
were removed by partial trypsinization, since fibroblasts would unstick faster than 
keratinocytes when Trypsin (Sigma Aldrich) was added. Then, the GSE4 #157 
keratinocytes were cultured in a fifth T75 flask with Kca and new feeder cells. 
The hydrogels for in vitro skin developments were made in 6 well plates containing a 
porous membrane (1µm), since a liquid-air interface was needed (DD Biolabs).  First, 
fibroblasts at a density of 1·10
5 
fibroblasts/well coming from the healthy and the DC 
#157 patients were added to each transwell (1 mL). The hydrogel (Vf=3,5 mL) followed 
the clotting cascade naturally found during wound healing, in vitro reproduced by 
adding to each transwell:  
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1) 1,5 ml Kca, in order to get to the desired final volume, 3,5 mL. 
2) 30 µl antifibrinolytic Amchafibrin (Fides Ecopharma) which prevented 
fibrinolysis during fibrin interaction with proteases. 
3) 250 µl bovine plasma thrombin (Sigma Aldrich) in CaCl2 25 mM, since both of 
them activated the clotting cascade and the reaction of fibrinogen into fibrin. 
4) Finally, 750 µl of porcine cryoprecipitate (Sigma Aldrich) was added. This final 
element contained fibrinogen, thus being the main responsible of creating the 
skin matrix. Once this element was added, gelation quickly took place. 
Therefore, this step had to be quickly performed with a 5 ml pipette.  
 
Two hours after the creation of the hydrogel, Kca was added to the top and to the 
bottom of the transwell. The keratinocytes we worked with during the experimental 
procedure were epidermal stem cells with the ability to divide unless differentiation 
took place; this step was performed in order to avoid keratinocytes differentiation 
during gel creation caused by high concentrations of calcium. Since the added Kca 
media absorbed calcium, calcium concentration was balanced. Keratinocytes would be 
allowed to terminally differentiate 17 days after creating the gel, during gel maturation. 
As shown in Fig 18, three fibrin gels were made for the control healthy groups, whereas 
six gels were made with patient #157’s fibroblasts – three of which would grow control 
keratinocytes, and the other three the GSE4 transduced keratinocytes. 
  
Fig 18: Diagram of the 6 well plates for the fibrin gels. (A) #157 patient, in which all transwells were seeded with 
Dyskeratosis Congenita #157 patient's fibroblasts. (B) Control sample, grown with healthy fibroblasts. 
 
Cell Seeding. 
Two days after the creation of the fibrin gels, keratinocytes were added to the 
corresponding gels. In order to perform this, the T75 flasks were trypsinized twice: once 
to remove the feeder cells, since the fibrin gels already had the patient’s fibroblasts, and 
A B 
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twice to unstick the keratinocytes. Half of the keratinocytes from GSE4 #157 and 
Control #157 samples were kept in cryopreservative Dimethyl Sulfoxide [DMSO, 
(Sigma Aldrich)] for prolonged maintenance. 
Keratinocytes on top of the gels were allowed to grow until confluence. Media was 
changed at the top and the bottom of the transwells every three days. 
 
Keratinocytes Differentiation. 
Once fluorescence microscopy inspection showed that top keratinocyte layer was 
homogeneously fluorescent in the gels, keratinocytes differentiation was initiated. This 
step took place 8 days after gel creation for #157 samples, and 17 days after in the case 
of the healthy samples. 
In this step, the gels were moved to bigger volume transwells (Fisher Scientific). The 
top of the gels was dried, which would induce keratinocytes differentiation at the air-
liquid interface by the previously explained mechanism of increased calcium 
concentration. 10 mL of differentiation media (Kca with 0,5% serum) were added to the 
bottom of the transwells. The big volume of the transwells would avoid the top layer of 
the gels to get in contact with any media by accidental capillarization.  
The organotypic cultures were allowed to further differentiate at 37ºC in a CO2 
incubator during twenty-one days, media being changed twice per week, after which the 
histological procedure was started.  
A timeline of the 3D Co-culture for the Construction of a Bioengineered Treated Skin 
Equivalent is shown in the diagram below: 
 
Table 3: Timeline of the second step of the experimental procedure, in vitro skin development. 
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3. Histology of the Bioengineered Treated Skin Equivalent 
 
Fixation.  
The grown skin equivalents were removed twenty-one days after differentiation was 
started. Every gel was aimed to undergo both paraffin sectioning and cryostat sectioning, 
therefore every gel was removed from the transwell and cut into two halves. Half of the 
tissue would be embedded in Tissue-Tek [Optimal Cutting Temperature compound, 
(Sakura Finetek)], a matrix for cryostat sectioning, and kept at -20ºC. The other half 
would be immersed in Formaldehyde (Sigma Aldrich) for fixation. Fixation preserved 
the tissue structure and prevented decay, by stopping enzyme activity. The tissues 
stayed immersed in formaldehyde for four days, and then further processed. 
 
Processing. 
The skin samples were then gradually dehydrated before being embedded in paraffin 
wax, which would serve as a solid support during sectioning. In a series of consecutive 
compatible steps (Table 4), the samples were first immersed in hydrophilic 70% ethanol, 
then in xylene as an intermediate step, and finally in hydrophobic paraffin (liquid at 
60ºC). The first step was performed manually, whereas the second last steps were 
performed by LEICA ASP 3005
 TM
 tissue processor at CIEMAT research center. 
 
Table 4: Fixation and processing during histological preparation. 
 
Sectioning. 
Those samples that would be sectioned with a microtome were first embedded in 
paraffin wax (solid at 20ºC) in the proper orientation. Fifteen histological sections of 2-
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5 µm were obtained from each sample, divided in three groups of five sections obtained 
at different depths from the sample. Therefore, in total 135 histological slides were 
obtained. The histological slices were gently placed in 40ºC water right after their 
sectioning, and then manually adhered on glass slides. 135 sections were also obtained 
using cryostat sectioning. In this case, the samples were embedded in Tissue-Tek in 
order to achieve the desired orientation, which hardened at low temperatures (-12ºC) 
thus allowing cryostat sectioning.   
 
Staining. 
Finally, the histological sections were stained with Hematoxylin and Eosin Stain (Sigma 
Aldrich). Hematoxylin stained acidic nuclear components, whereas eosin stained basic 
cytoplasmic and extracellular components. In this procedure, gradual rehydration was 
performed before infiltration in the hydrophilic stains: 
1) The histological sections obtained from cryostat sectioning were first immersed 
in PBS, and then kept for ten minutes in a mixture of methanol and acetone at -
20ºC. 
2) The paraffin histological sections were immersed in xylene for dissolving 
paraffin, and then rehydrated by being passed through several changes of alcohol.  
3) Every histological section – both from paraffin and from cryostat sectioning – 
was rinsed in water. 
4) Hematoxylin stain was applied 8 minutes 
5) The sections were rinsed in water and immersed in a weak alcohol for one 
minute, which would remove non-specific background staining. 
6) The sections are rinsed in water, and then “blued” for one minute with a weakly 
alkaline solution, which converts hematoxylin into a dark blue color. 
7) Eosin stain was applied for one minute. 
8) The histological sections were again dehydrated by passing through a series of 
ethanol infiltrations and final immersion in xylene. 
9) Mounting with a layer of polystyrene and a glass cover slip (Fisher Scientific). 
Then, the histological slides could finally be observed under the optical microscope. If 
the first microscopy inspection was favorable, then further immuhistochemistry staining 
would be carried out with the cryostat histological sections.   
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Results 
 
In the herein section, the results obtained during the research project will be presented 
following a chronological order. Results will be separated into the three main stages of 
the experimental procedure:  
First, the different keratinocytes populations cultured and amplified after lentiviral 
transduction were studied using optical microscopy. The transduction efficiency was 
evaluated under blue-light fluorescence microscopy. 
Next, the 3D culture of transduced keratinocytes and control ones in the bioengineered 
skin equivalents was observed under optical microscopy. 
Finally, the bioengineered skin equivalents were analyzed following histological 
procedures and later stained with H&E technique. The bioengineered histological 
samples were analyzed using optical light microscopy. 
However, it is important to remark that the amount and quality of the results also 
followed the above described decreasing order: Lentiviral transduction of the 
keratinocytes yielded better results than the bioengineered skin equivalent. Therefore, 
and also considering that the successful transduction was the ultimate goal of our 
research line, most of the results will be focused on this primary stage of the project. 
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1. Lentiviral Transduction of Keratinocytes 
 
The GSE4 and Control GFP lentiviruses were created in 293T packaging cells before 
being isolated for keratinocytes infection. Fig 19 represents the 293T cell culture in 
which control GFP lentiviruses were grown. On the left, a bright-field microscopy 
image is displayed. On the right, the superposing fluorescence image is presented. Both 
images correspond to the same section in the cell culture. The positively fluorescent 
colonies in Fig 19 B indicate that the lentiviruses had been successfully constructed 
from the added components, and that they were functional and expressing the GFP gene 
from the construct. 
 
Fig 19: 293T cells under fluorescence microscope, showing that the GFP control constructed lentiviruses were 
functional. (A) Bright-field microscopy image. (C) Blue-light fluorescence image. 
 
Due to the structure of the genetically engineered lentivirus, fluorescence would serve 
as a double reporter of successful lentiviral transduction. First, in all cases of lentiviral 
infection, fluorescence would imply that the lentivirus had successfully integrated its 
genetic material into the keratinocytes genome, which would be regularly expressing the 
GFP gene. And secondly, in the particular case of those DC keratinocytes infected with 
GSE4 + GFP, due to the presence of IRES in the transduced transgene, a fluorescence 
result would imply that the GSE4 gene was also being coexpressed – that is why GFP is 
considered to be a double reporter. 
The cell culture at Fig 20 below belongs to those keratinocytes from Dyskeratosis 
Congenita patient #157 five days after being infected with GSE4 + GFP lentivirus. The 
keratinocytes colony pictured at Fig 20 A was successfully expressing GFP, so it can be 
inferred that GSE4 was also being expressed. 
A B 
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Fig 20: GSE4 #157 Keratinocytes five days after lentiviral transduction. (A) Bright-field image of the cell culture 
was an indicator of cell viability and proliferation. (B) The superposing fluorescence image of the same capture 
indicated successful transduction. 
 
The day the pictures above were taken, the different keratinocytes populations were 
allowed for amplification. We were working with five samples in total: two GSE4 
treated DC patients (#157 and #64) and three infected but untreated control samples 
(#157 and #64 DC patients and one healthy patient). These cell cultures were allowed 
for proliferation during three weeks, at the end of which the GSE4 transduced 
keratinocytes were exclusively selected in terms of their fluorescence through cell 
sorting. Fig 21 shows the percentage of GSE4 #157 keratinocytes that successfully 
passed the fluorescence sorting. A 97% of the original cells remained after sorting, 
meaning that up to a 97% of the infected GSE4 #157 keratinocytes had been indeed 
successfully transduced by the lentivirus. 
 
Fig 21: Output from the sorting equipment for cells GSE4 #157. A 97% of the cells remained after selective 
sorting. 
A B 
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The remaining keratinocytes were again allowed for proliferation, but this time there 
was a 100% certainty that every cell in the culture had been successfully transduced. 
The figures below represent the keratinocytes cultures after amplification. Fig 22 
represents the same #157 GSE4 line that was already pictured at Fig 22 three weeks 
after the previous capture. The homogeneous fluorescence along the whole culture 
proves that sorting had been successful, since all the cells in the culture were 
successfully expressing GFP.  
 
Fig 22: GSE4 #157 Keratinocytes after selective sorting. (A) Optical image of the cell culture shown confluency. 
(B) The superposing fluorescence image of the same capture indicated the homogeneous succesful lentiviral 
transduction along the whole cell culture. 
 
Fig 23 below represents those keratinocytes from the same patient, #157, but belonging 
to the control study: they had been only transduced with GFP gene. Fig 23 B shows how, 
in contrast with Fig 22, these cells had not been selectively sorted since regions not 
expressing GFP could be distinguished.  
 
Fig 23: GFP #157 Keratinocytes after amplification, no sorting was applied. (A) Optical image of the control 
group. (B) Superposing fluorescence image indicating lentiviral insertion in the host's genome, although not with a 
100% of efficiency. 
A
  B 
B
  B 
A
  B 
B
  B 
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 On the other hand, the transduced keratinocytes from patient #64 exhibited an abnormal 
shape, shown in Fig 24 A, which will be later discussed. Since this moment, and even 
though it exhibited fluorescence (Fig 24 B) and therefore successful transduction, 
patient #64 was deleted from our experiment.  
 
Fig 24: GSE4 #64 Keratinocytes after selective sorting. (A) The optical image shown some abnormal cellular clots. 
For this reason, patient #64 was not further used along the experimental procedure. (B) Superposing fluorescence 
image showing successful lentiviral transduction. 
 
In conclusion, results show how lentiviral infection and genetic integration had been 
successful along all the keratinocytes. Only the successful and reliable results were 
considered for the next stage of the experimental procedure.   
 
  
A
  B 
B
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2. 3D Co-culture for the Construction of a Bioengineered Corrected 
Skin Equivalent 
 
After assuring that gene therapy had been successful, meaning that the prepared 
lentivirus had transduced the patient’s keratinocytes and that the engineered plasmid 
had inserted in the genome of the epithelial cells, an in vitro skin model was constructed 
using the modified cells as the building blocks. The objective was to assess whether the 
genetically treated cells grew normally and developed a healthy phenotype. 
As expected, the seeded fibroblasts and keratinocytes self-assembled themselves in the 
natural structure of skin. Fig 25 and Fig 26 were obtained using optical microscopy 
from the top of the samples. Therefore, the 3D layered structure of the skin could be 
distinguished in the results: keratinocytes and fibroblast would belong to different 
planes and would not be able to be focused simultaneously. 
 
Three transwells containing the skin equivalent were prepared from each sample, having 
in total three samples (and therefore, nine skin equivalents, as represented previously in 
Fig 18). The three samples to be 3D cultured were: 
i. Patient #157 transduced with the GSE4 lentivirus: This sample was genetically 
treated against DC.  
ii. Patient #157 transduced with the GFP lentivirus: This sample was a control for 
the genetic treatment. 
iii. Healthy, non- transduced patient: This sample was a control for the in vitro 
experiment. 
 
Fig 25 and Fig 26 below represent the appearance of the 3D culture four days after 
seeding the transduced keratinocytes from patient #157 in gels (i) and (ii). Fig 25, 
belonging to the GSE4 treated sample (i) grew normally along the expected lines of 
development. In the microscopy pictures, the almost confluent keratinocytes could be 
distinguished above the underneath layer of fibroblasts. Fig 26 represents the control gel 
(ii). In this case, the gel had developed some undesired clots of cells, which could be 
distinguished by their abnormal size and brown color.  This result will be later analyzed 
in the section of discussion.  
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Fig 25: Fibrin hydrogel seeded with GSE4 #157 keratinocytes. 
 
 
Fig 26: Control fibrin hydrogel seeded with GFP keratinocytes. 
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3. Histology of the Bioengineered Treated Skin Equivalent 
 
Along preliminary studies, our team has already successfully developed an in vitro 
model of DC skin from patient’s keratinocytes and fibroblasts [68]. In Fig 27, a 
representative image of the obtained result, taken at 10x, is displayed. 
 
Fig 27: In vitro bioengineered skin from: (A)  Healthy cells. (B) DC cells. [68] 
 
In the present study, these preliminary results were corrected since the in vitro skin was 
grown from GSE4 transduced DC cells, whereas the previous study worked with 
untreated DC cells.  
 
Returning to the last results of our bioengineered skin equivalents described in the 
previous section, the organotypic culture or 3D co-culture in the fibrin matrix was 
allowed to mature until successful terminal differentiation was achieved. This event was 
considered to happen 21 days after keratinocytes differentiation was started, and it could 
be visually assessed by the formation of a white coat on top of the hydrogel, shown in 
Fig 28. This layer would correspond to the keratinized Stratum Corneum, indicating that 
epidermal stratification was completed. 
 
Fig 28: In the completely differentiated in vitro skin the stratum corneum can be distinguished. 
Once this differentiation was reached, the prepared gels then went through the 
traditional histological procedure, consisting on fixing, processing, embedding in 
paraffin and sectioning the sample. They were stained with Hematoxylin and Eosin 
(H&E staining) and the glass slides were analyzed under optical microscopy and the 
outcome, which did not yield as expected, will be discussed in the next section. 
A
  B 
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Discussion 
 
In this section the previously presented results will be further analyzed by comparing 
them with those obtained during different researches, and a critical discussion on the 
strong and weak points of our project will be performed. 
 
 
1. Lentiviral Transduction of Keratinocytes 
 
The main finding of the first section of the project, and moreover of the whole study in 
itself, is the unprecedented high efficiency of transduction by the GSE4 vector in the 
DC keratinocytes. The keratinocytes obtained from Dyskeratosis Congenita patients 
were transduced twice with the correcting GSE4 lentiviral vector, and the positive 
results could be observed significantly early, as shown in Fig 20 five days after 
transduction. The keratinocytes successfully expressed the GFP protein, encoded in the 
transgene and connected by coexpression with the therapeutic gene GSE4 through the 
Internal Ribosome Entry Site (IRES), as Fig 15 previously represented.  
Whereas fluorescence was a qualitative way to assess GSE4 transduction, cellular 
sorting provided a quantitative indicator. Cell sorting provided a means to transduction 
selection using fluorescence as the discriminant factor: fluorescent cells passed the 
fluorescent test and were recovered for posterior cell culture, whereas non-fluorescent – 
and thus, non-corrected- cells were rejected. Fig 21 represented how the output 
keratinocytes that remained after cellular sorting included a 97% of the initial 
input keratinocytes. This result illustrates how GSE4 transduction was extremely 
efficient and very close to complete correction. 
Moreover, Fig 22 showed how the GSE4 transduced cells successfully divided as can 
be inferred from the expansion of the green fluorescent area (corresponding to the 
corrected cells) when comparing Fig 20 and Fig 22, which belong to the same GSE4 
transduced sample but with three weeks of difference. This cellular proliferation is also 
an indicator of successful genetic correction against DC since DC cells are characterized 
for early undergoing cell senescence and quitting cell division [69]. On contrast, our 
GSE4 keratinocytes behaved as healthy cells in terms of proliferation. 
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The efficiency in GSE4 transduction was considered to be the most remarkable 
achievement in the present study not only because it was a pioneer work on gene 
therapy for Dyskeratosis Congenita, but because it yielded much more positive results 
than prior studies carried out by our team. Preliminary experiments were performed 
using the precursor of GSE4: GSE24.2 transgene is equivalent in function to GSE4 but 
different in structure. Nevertheless, in contrast with the results obtained in this 
experiment with GSE4 (Fig 15), preliminary infection with GSE24.2 vectors did not 
yield any successful transduction, as shown in Fig 29 [68]. 
 
Fig 29: GSE24.2 #157 keratinocytes after lentiviral infection. (A) Bright-field microscope image. (B) Blue-light 
fluorescence microscopy image for assessing GSE24.2 expression. [68] 
 
As previously stated during the review of the state-of-the-art, GSE4 is actually a 
fragment derived from GSE24.2. However, it yielded positive results in transduction 
whereas its precursor did not. In order to analyze this difference in transduction, the 
difference in structure between the two genes will be studied. Comparing their peptide 
sequence, represented in Fig 30, GSE4 is an 11 amino acids-long peptide corresponding 
to the N-terminal region of GSE24.2, which has a length of 55 amino acids [65]. 
 
Fig 30: Amino acids sequence of GSE24.2 and its 11 amino acids-long derivation, GSE4 [65]. 
 
GSE4 is five times shorter than its GSE24.2 peptide and this has most likely made a 
determining difference in transduction. Its shorter size has allowed it to easily penetrate 
into the cell during lentiviral infection, whereas GSE24.2 was too big to cross the 
cellular barriers. This enhanced transduction gave GSE4 a decisive advantage in the 
development of a gene therapy for DC over GSE24.2, and placed it as the target peptide 
for further researches along this line. 
B A 
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Regarding these results in transduction, further elements need to be discussed, such as 
the IRES component in our GSE4 transgene. The Internal Ribosome Entry Site (IRES) 
allows the co-expression of the therapeutic and the reporter gene under the same 
promoter in order to facilitate a direct, visual result on the gene of interest. During 
translation, IRES binds to the 40s ribosomal subunit in such a way that gene expression 
is forced to continue into the next gene [70], as shown in the diagram below. 
 
Fig 31: Mechanism of IRES during translation. In our study, the promoter was CMV, the gene of interest was 
GSE4, and the reporter gene was GFP [70]. 
 
IRES is the most common strategy used by researchers to ensure co-expression since it 
saves time and significantly increases the percentage of double transgenic offspring. 
Nevertheless, it is important to take into account that IRES also implies some 
drawbacks and that co-expression of the two genes is not always necessarily equally-
balanced, meaning that one gene can be expressed with more efficiency than the other 
[71]. As a result, in the case of our experiment even though GFP expression did imply 
GSE4 expression, the relationship in expression did not have to be necessarily directly 
equivalent. Further experiments on the quantification of GSE4 expression should be 
performed to evaluate this possibility. On the other hand, in order to avoid this 
impairment, alternative ways for co-expression could be considered. For example, the 
synthetic creation of an only polyprotein containing the sequences of several proteins 
that will be simultaneously co-expressed would solve the unbalanced co-expression 
while avoiding the use of the large size IRES sequence (~0.5 kB) [72]. 
 
Another important point of discussion is the GSE4 transduction results on patient 
#64, previously displayed in Fig 24. Patient #64’s keratinocytes were transduced with 
the GSE4 vector along with patient #157’s cells. Nevertheless, GSE4 #64 keratinocytes 
yielded different results to GSE4 #157 under the same conditions. As Fig 24 B 
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represents, GSE4 #64 showed also successful transduction. However, the morphology 
in the #64 cells turned to be abnormal whereas #157 cells grew normally: #64 
keratinocytes exhibited abnormally large cellular clusters that could be explained 
through different hypothesis. On the one hand, the skin cells could have accidentally 
differentiated therefore creating the characteristic keratinized stratified structure of 
natural skin [73]. On the other hand, some protoncogenes might have been accidentally 
activated by the HIV-1 lentivirus promotor, therefore developing abnormal, malignant 
keratinocytes [74]. A comparison between GSE4 #64 results (Fig 32 A) and 
representative cell cultures from the two proposed hypotheses is shown in Fig 32, in 
order to visually facilitate a diagnosis of the abnormalities presented by GSE4 #64 
keratinocytes. Further research should be carried out in order to confirm or reject these 
hypotheses. 
 
Fig 32: Comparison between abnormal keratinocytes cultures caused by different conditions. (A) GSE4 #64 
keratinocytes after sorting and amplification showed an abnormal morphology. (B) Differentiated keratinocytes in 
cell culture caused by high calcium concentrations [73]. (C) Malignant keratinocytes surrounded by fibroblasts, 
obtained from an epidermal tumour [74]. 
 
In order to avoid a potential oncogenesis and gene disruption caused by the random 
insertion of the GSE4 HIV-1 lentivirus in the host’s genome, a suicide gene could be 
added to the vector in order to eliminate the therapy if oncogenic conditions developed. 
As an example, Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK) has been 
recently found to be a good candidate for suicide gene therapy [75]. 
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2. 3D Co-culture for the Construction of a Bioengineered Corrected 
Skin Equivalent 
 
During this section of the experimental procedure, the skin structure was reproduced 
based on a 3D fibrin scaffold. The dermis was formed from the patient’s fibroblasts that 
had been seeded in this fibrin matrix, which released collagen and formed a mature 
extracellular matrix that would replace the temporal fibrin scaffold and form the mature 
dermis. On the other hand, the formation of the epidermis had followed two stages: first, 
the corrected keratinocytes were seeded in order to form a confluent epidermal 
monolayer on top of the fibrin matrix; then, this monolayer of keratinocytes was 
differentiated by calcium gradient, inducing the characteristic epidermal stratification 
[52]. In the results displayed in Fig 25 and Fig 26, the different planes at which the 
dermis (fibroblasts) and the epidermis (keratinocytes) are located can be distinguished 
due to the focal differences. 
However, the results obtained in Fig 26 need to be further discussed. This sample, 
which corresponded to GFP #157 control keratinocytes, developed some undesired clots 
of cells which exhibited a characteristic brown color and abnormal shape. In order to 
analyze this outcome, two possible causes could be considered. The first hypothesis is 
that the keratinocytes could have accidentally undergone premature differentiation 
during the experimental procedure. In this case, dead keratinocytes would have 
accumulated in the top stratum corneum before the complete development of the rest of 
the layers in the epidermis was fulfilled. A review of the reasons behind keratinocytes 
premature differentiation was published in 2013 by Borowiec et al., indicating that this 
complex process requires multifactorial external control [76]. However, this hypothesis 
would not explain why only the GFP #157 control samples yielded these results. 
An alternative explanation would be that these cellular clots were simply the natural 
phenotype in Dyskeratosis Congenita samples. In this case, this abnormal result would 
indeed be desired, since the role of the control sample is to reproduce the sick DC 
epidermal manifestations. However, in order to evaluate this hypothesis, further 
immunohistochemically studies should be performed on this sample and compared with 
an untreated DC skin model. 
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3. Histology of the Bioengineered Treated Skin Equivalent 
 
In this final stage of the experimental procedure, the two previous stages would be 
commonly assessed by histology of the in vitro skin prepared from corrected 
keratinocytes. Unfortunately, when studying the histological slides, the results did not 
yield as expected.  Under optical microscopy, none of the prepared skin equivalents 
presented the epidermis layer. Since the axis of our project was the genetic correction 
of the keratinocytes, which precisely belong to this undeveloped epidermis layer, and 
since the phenotype of DC manifests mainly in the epidermis, the obtained results did 
not represent the object of our study. Therefore, further analysis such as 
immunohistochemistry in order to more specifically in vitro assess the success of the 
gene therapy could not be performed. 
This adverse result was indeed caused by accidental bacterial contamination of the 
bioengineered skin during manipulation and transport. The bacteria had proliferated 
around the in vitro skin samples and released toxins that destroyed the cells on the 
developing epidermis. The main solution to avoid these unfortunate results would be to 
repeat the experimental procedure and grow new skin equivalents under more 
controlled sterile conditions. 
 
Theoretically, a similar result should have been obtained throughout the healthy grown 
skin equivalents and those developed from GSE4 corrected keratinocytes. If gene 
therapy had been successfully applied – which, theoretically, indeed was due to the 
results explained in the first section of the present discussion – the DC keratinocytes 
would have recovered their healthy function and normal skin would have developed. 
Healthy skin, previously represented in Fig 27 A from preliminary studies, exhibits a 
homogeneous thickness of the epidermal layer and the correct formation of the Stratum 
Corneum on top of this epidermis. In addition, the epidermal-dermal junction that 
attaches the two layers of the skin is properly developed in healthy skin, as well as the 
matrix of dense connective tissue embedding the fibroblasts in the dermis [68]. 
On contrast, the GFP control skin equivalents should exhibit the characteristic 
histological structure of DC, represented in Fig 27 B. Comparing the histology of 
healthy and DC skin, the differences characteristic of the disease are easily visible. In 
DC skin, the Stratum Corneum is abnormally thick and dense in a hyperkeratotic 
behavior, compared with the linear and homogenous St. Corneum in healthy skin. 
Moreover, the entire epidermis presents a hyperplasic phenotype in which cells 
abnormally grow in number while maintaining a normal morphology, resulting in an 
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increase in volume of the epithelial tissue. On the other hand, the dermis in diseased 
skin is formed by loose connective tissue with a reduced number of collagen fibers, 
compared with the dense CT found at the dermis of the healthy skin. This loose dermal 
conformation reduces the mechanical properties of the whole skin. Finally, the 
attachment between dermis and epidermis in DC skin is practically null along the 
dermal-epidermal junction, facilitating the detachment of epidermis and reducing the 
functionality of the skin [10] [68]. All these features of diseased skin are outlined in Fig 
33. However, the presence of different protein markers should be assessed by 
immunohistochemistry in order to quantify these qualitative results. 
 
Fig 33: Histological image from in vitro DC skin model. The main differences with healthy skin are highlighted. 
 
All these characteristic features of DC skin are correlated between themselves, and 
fundamentally caused by the impaired function of DC keratinocytes. The hyperplasia at 
the epidermis might induce the hyperkeratosis at the St. Corneum. The diseased 
behavior of DC keratinocytes might decrease the attachment at the dermal-epidermal 
junction, which would influence the composition of the dermal layer. In addition, DC 
fibroblasts are known to exhibit proliferative defects, as any other cell suffering from 
telomerase shortage [77]. This reduced number of fibroblasts would explain the loose 
conformation of DC dermis. 
 
As stated previously, the experimental procedure should be repeated in order to 
guarantee that these theoretical results indeed coincide with the empirical results. If 
such an accordance happened, then GSE4 therapy for Dyskeratosis Congenita would be 
proved to be successful and further clinical trials could be performed in the pursue of a 
standardized treatment of the disease. 
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Conclusion 
 
As a conclusion, the present project has achieved for the first time the genetic 
correction of Dyskeratosis Congenita in patients’ keratinocytes, since no previous 
studies on gene therapy for this rare disease have been reported in the literature so far. 
The obtained positive results have empirically proven that a future treatment based on 
gene therapy is viable, opening the path to a new therapeutic approach that would 
address DC at its core and dramatically reduce the cases of this rare disease. 
The transgene that was used in the present study was GSE4, a short peptide derived 
from the mutated DKC1 gene in X-linked recessive Dyskeratosis Congenita. GSE4 was 
found to be unprecedentedly successful for DC correction, on contrast with its precursor 
GSE24.2 which was used in preliminary studies but did not yield positive results in DC 
correction. Even though GSE4 and GSE24.2 share many common features, the 
difference in their correction efficiencies lies in the lengths of the peptides: initial 
GSE24.2 is 55 amino acids-long, whereas final GSE4 presents a reduced length of 11 
amino acids which enhanced lentiviral infection in target cells during gene therapy. This 
length reduction provided GSE4 with a significant efficiency advantage over alternative 
transgenes while maintaining the therapeutic effect and functionality. 
Moreover, the present project has studied the consequences of premature keratinocyte 
differentiation on in vitro skin equivalents, as well as the effects of HIV-1 vector 
integration near the transcription start site of a protooncogene during gene therapy. 
These results were visible during cell culture due to the abnormal morphology of the 
keratinocytes, and should be avoided in order to achieve reliable in vitro models.  
Even though the present study gives the first step in the search of a gene therapy for 
Dyskeratosis Congenita, more steps await before this treatment could become a reality. 
The next studies to be performed after the herein presented results would be the 
development of models using the GSE4 corrected cells, in order to evaluate whether 
they indeed behave as healthy tissue. In the present project, an in vitro skin equivalent 
was grown using the GSE4 modified keratinocytes as the building blocks; however, this 
in vitro model should be further analyzed through immunohistochemistry techniques as 
well as telomere measuring tools. On the other hand, in vivo models are also of great 
importance for determining the viability of gene therapy: the in vitro skin would be 
transplanted as a graft in immunodefficient mice, and the in vivo behavior of the graft 
would be evaluated. In vivo studies are fundamental as preclinical models, and if the 
GSE4 corrected cells yield the expected in vivo behavior, a DC treatment will be closer 
to be real for all those persons suffering from this rare disease. 
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Alternative Applications and Future Work 
 
The results obtained in the present study have opened a promising path of research in 
gene therapy for Dyskeratosis Congenita in which the steps to follow are already well-
defined. After the successful GSE4 cellular correction, the most coherent study to 
perform next would be an in vitro skin model built from these corrected DC cells to 
study their behavior. This model was already developed in the present project, although 
further studies should be performed at this stage. Immunohistochemical tools should 
be applied to the samples in order to visualize the presence or absence of specific DC 
antigens in the in vitro model. For instance, Filaggrin/Loricrine could be studied to 
evaluate terminal differentiation in epidermal layer, or Prolyl 4-Hydroxilase for 
collagen synthesis. Also, the correction of DKC1 gene with GSE4 transgene could be 
assessed with α-myc antibodies, which allow visualizing the cellular localization of 
dyskerin; since dyskerin is a nucleolar protein, if GSE4 gene therapy was successful, α-
myc should be found at the nuclei. Finally, telomere assays could be carried out in 
these in vitro models since DC is essentially a telomeropathy implying a decrease in 
telomere length.  
The successful development of a gene therapy for Dyskeratosis Congenita would be a 
milestone in the emerging field of regenerative medicine at its whole, not only for DC 
patients. Since GSE4 codes for the dyskerin subunit of the telomerase complex, a 
therapy based on this transgene could be applied to other telomeropathies that have 
their roots on an impaired telomerase activity, such as Aplastic Anemia or Cri Du Chat 
syndrome. 
 
Regarding alternative designs to address the same goal targeted during this project, 
many different approaches based on emerging technologies and future medicine could 
be chosen to study DC other than the 3D in vitro models used in the present study. 
Lately, organ-on-a-chip technology has been rapidly developed as a simple, cheap and 
easily customizable way to create miniaturized models of organs. The main 
characteristics of the organ of interest are mimicked with equivalent elements in a 
microfluidic device, and the function of the organ as a whole is reproduced at the micro-
scale. Skin-on-a-chip models could be readily customized with DC cells as well as 
GSE4 corrected cells in order to easily study the characteristic proliferation, telomerase 
activity or DKC1 expression in these cells. 
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On the other hand, alternative approaches to treat DC other than the GSE4 lentiviral 
transduction used in the present study could also be considered within the same 
framework of gene therapy. CRISPR/Cas9 is a recently discovered genome editing tool 
that could replace the HIV-1 lentivirus used as the vector for gene therapy in this project. 
Theoretically, CRISPR/Cas9 could be customized to delete the mutated DKC1 gene in 
X-linked recessive DC, as well as to insert the healthy transgene GSE4 in the host’s 
genome. The desired CRISPR/Cas9 complex could be delivered into the target cell 
through inorganic and organic particles, such as lipoplexes, which would not present the 
immunogenicity risks inherent in viral vectors. Even though this CRISPR/Cas9 
approach is yet to be studied, it stands firmly as a potential alternative to HIV-1 
lentivirus in DC gene therapy. 
Finally, an alternative approach to diagnose DC instead of the currently used 
histological tools would be the genome sequencing tools, which have rapidly evolved 
since the recent rise of the field of genomics. Next Generation Sequencing techniques 
such as Illumina® genome analyzer could be used to readily analyze the patient’s 
genome in the search of a mutation in DKC1 gene; also, Illumina® could rapidly 
sequence the telomere in order to diagnose whether abnormal telomere shortening is 
taking place. Moreover, recently new prototypes of future Next Generation Sequencing 
platforms have been developed, such as the small Oxford Nanopores® which would 
provide a simple and immediate diagnosis of DC through a new genome sequencing 
technology based on measuring the current produced by the nitrogenous bases at DNA.   
Next Generation Sequencing platforms would avoid the time and difficulties implied in 
histology for current diagnosis. 
 
Dyskeratosis Congenita is a broad pathology, and the more it is studied, the more this 
broadness increases: New genotypic mutations are found to cause the disease, and more 
phenotypic manifestations are found to be related with it. Currently, DC comprises a big 
complex network of genes and characteristics with no apparent linear relationship 
among them. Taking into account this heterogeneity, it is logical to understand that most 
probably a combination of different approaches will be determinant for finding a final 
cure to Dyskeratosis Congenita. In particular, the broad range of phenotypic 
manifestations in DC patients leads to think of Systems Biology as a logical step during 
the study of the disease. In Dyskeratosis Congenita, the mutation of a single gene within 
the telomerase complex leads to failures in many different organs throughout the body: 
skin, lungs, liver, bone marrow,… Initially these organs might appear to be functionally 
unrelated, but in Dyskeratosis Congenita they all share a common origin of failure. 
Therefore, thinking of this multisystem disease as a network, there is a chance that we 
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have overlooked at a possible connection between two elements in the network that 
could be critical for the discovery of a cure for DC. In conclusion, studying 
Dyskeratosis Congenita from a systemic approach would allow for the comprehensive 
understanding of the relationships between the simultaneous mutations and 
malfunctions throughout the whole body during the disease. 
In conclusion, there are many different approaches that could be complementarily taken 
in order to understand Dyskeratosis Congenita, as well as many techniques in order to in 
vitro study the disease. However, once the condition has been understood, the treatment 
is what, at the end, makes a difference. And in terms of treatment, the only real way to 
address the problem at its core is to cure the genetic mutation at DKC1. Therefore, gene 
therapy stands out as the only real solution against Dyskeratosis Congenita, targeting 
the problem at its very root. Even though the most efficient gene therapy technique is 
yet to be found or perfected, huge improvements are continuously being made in this 
line and most likely this rare disease will be overcome by future medicine in the next 
years. 
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Annex I: Legal Regulatory Framework 
 
The present Final Year Project is framed into a biomedical scientific research activity, 
which is recognized as a fundamental right of maximum protection by the Article 20.1.b of 
the Spanish Constitution of 1978.  
Furthermore, the specific legal regulation of biomedical research is stated at Law 14/2007 
of July 3th. However, this law was partially modified by Law 14/2011 of Science, 
Technology and Research.  
At the international level, Law 14/2007 belongs to the Convention of the European 
Council for the protection of human rights and dignity of the human being regarding the 
application of biology and medicine. This Convention was signed in Oviedo on 14TH April 
1997 and was applied in Spain since the 1st January 2000. In this law it is proclaimed that 
the health, dignity and welfare of the human being participating in biomedical research will 
prevail over the interest of society or science.  
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Annex II: Project Planning 
 
The execution of the whole project can be divided into the following five stages, which 
have been already mentioned throughout the present memory: 
1.- PRELIMINARY STUDY. First reunion with the project tutor and setting up of 
the goals. Contextualization of the project, primary planning, and initial 
literature search………………………………………………………......10 hours 
2.- GENE THERAPY. Construction of the lentiviral vectors, transduction, and 
amplification of the corrected cells………………………………………60 hours 
3.- BIOENGINEERED SKIN. Development of a fibrin-based in vitro skin 
equivalent from the corrected cells. Terminal keratinocytes differentiation until 
epidermal stratification is completed…………………………………… 50 hours 
4.- HISTOLOGY. The in vitro skin was processed and sectioned into histological 
slides, which were later stained for microscopy inspection……………. 40 hours 
5.- DISSERTATION WRITING. The project was transcribed into the present 
memory, and several versions were sent for correction to the tutor. Final reunion 
with the tutor…………………………………………………………... 180 hours 
The project was regularly supervised by the tutor, with whom communication and 
discussion of the obtained results were continuous. Frequent reunions were arranged 
throughout the whole experimental stages with the tutor. 
Table 5 represents the estimated number of hours spent in every stage of the project, 
whereas the project timeline can be studied in Table 6, in which the relation between the 
weeks work and the tasks performed are related. 
 
Stage Hours 
1 10 
2 60 
3 40 
4 50 
5 180 
Total 340 
 
Table 5: Overview of the project in time units. 
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Table 6: Timeline of the project representing the relation between the weeks of work and the tasks performed 
 Stages 
Weeks 1 2 3 4 5 
1      
2  
Lentivirus in 
293T 
   
3  Infection of 
Keratinocytes 
   
4  Amplification    
5  Amplification    
6  Sorting    
7  Amplification    
8   
Fibrin 
Hydrogel + 
Seeding 
  
9   Development   
10   Differentiation   
11   Differentiation   
12   Completed 
Differentiation 
  
13    Fixation  
14    Processing  
15    Sectioning  
16    Sectioning  
17    Sectioning  
18    Sectioning  
19    Staining  
20      
21      
22      
23      
24      
25      
26      
27      
28      
29      
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Annex III: Budget and Production Cost 
 
A review of the production cost of the present project is described in Table 7, which 
represents the estimated expenses on personnel and on the different laboratory reagents 
and material consumed throughout the experimental procedure, considering the 
availability of the information at the user-level. A total amount of 2505,793€ was 
estimated to be spent in the performed project in reagents and laboratory consumables. 
However, it is important to highlight that not all the materials listed below were used in 
their totality, but only a part of each unit in most of the cases. This happened because 
the materials were shared with the whole Cell Culture Bioengineering Laboratory at the 
University Carlos III of Madrid.  
Similarly, the budget set aside for the project was included within the global budget of 
the laboratory. This budget comprises both the materials already mentioned in Table 7 
as well as the specialized equipment, which require periodic supervision and 
maintenance, as well as constant electronic supply: 
 CO2 cell incubators: 3517-SHEL LAB 
 Blue-light fluorescence microscope: BX53 OLIMPUS 
 Thermostatized water bath: BM 302 – NÜVE 
 Refrigerated centrifuge: Digtor 21-R ORTOALRESA 
 Biosafety cabinet: BIO-IIA-TELSTAR 
 Cell Sorter: BD Influx 
 Tissue Processor: LEICA ASP 3005 
 
This budget is financed by the research funds for University Carlos III of Madrid. In 
addition, part of these economical funds is designated to instruct every laboratory 
worker in biological safety. In the Cell Culture Bioengineering Laboratory, as in any 
other laboratory, the appropriate security protocol against potential biological risks was 
followed.  
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Table 7: Production costs of the project along the three experimental stages (continues in next page) 
Consumables 
Product Description Company Price/unit (€) Amount Consumed Cost (€) 
P100 dishes, 20/bag Fisher Scientific 134.03 9 units 11.56 
75 mL T-Flasks (case 30) Sigma Aldrich 257.4 10 units 85.8 
X50 Falcon Tubes 15 mL Sigma Aldrich 7.05 150 units 10.575 
X50 Falcon Tubes 50 mL Sigma Aldrich 8.12 70 units 22.736 
Electronic Pipettor DD Biolabs 48.89 1 unit 18.89 
X200 Serological Pipet Fisher Scientific 24.1 400 units 48.2 
X500 2 mL Microtube 
Naturel 
Fisher Scientific 7.65 500 units 7.65 
Micropipette Tip 200µL Labbox 36.191 400 units 14.48 
Micropipette Tip 10µL Labbox 6.02 400 units 2.408 
X100 Nitrilo Comfort 
Gloves S6,5 
Fisher Scientific 4 200 units 8 
   Subtotal 230.299 
Reagents: Gene Therapy 
DMEM High W/GlutaMax 
(500 mL) 
Fisher Scientific 20.38 3 L 122.28 
Keratinocytes Serum Free 
Medium (10X500 mL) 
GIBCO 772 5 L 772 
FBS 500 mL Fisher Scientific 106,4 500 mL 106.4 
293T cells ATCC 358 27 million 358 
Feeder cells ATCC 75 15 million 281.25 
Chloroquine Sigma Aldrich 39.3 3 µL 4.71 
Packaging Plasmids 
Donation from 
Dra Perona 
- 40.656  µL - 
PuraDisc Filter 0.2 µm Fisher Scientific 66.3 4 units 10.68 
Polybrene Sigma Aldrich 45.3 3.5 µL 7.92 
   Subtotal 1663.24 
Reagents: Bioengineered Skin 
Trypsin 100 mL Sigma Aldrich 14.9 70 mL 10.48 
6 Well Plates with Porous 
Membrane (1µm) 
DD Biolabs 271 2 units 10.84 
Amchafibrin Fides Ecopharma 3.14 30 µL 0.52 
Bovine Plasma Thrombin Sigma Aldrich 277.5 250 µL 277.5 
Porcine Fibrinogen Sigma Aldrich 311.9 750 µL 31.19 
Dimethyl Sulfoxide 50mL Sigma Aldrich 36.7 4 mL 2.936 
X50 Falcon Tissue Culture 
Plate  
Fisher Scientific 135.2 2 units 5.408 
   Subtotal 338.87 
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Reagents: Histology     
Product Description Company Price/unit (€) Amount Consumed Cost (€) 
Formaldehyde (1 L) Sigma Aldrich 62 1 L 62 
Tissue Tek OCT Compound Sakura Finetek 20,93 2 units 41,86 
Hematoxylin Stain (4L) Sigma Aldrich 238.5 500 mL 29.8 
Eosin Stain Sigma Aldrich 62.4 500 mL 62.4 
Xylene (5 L) Thermo Scientific 105 500 mL 10.5 
Ethanol 99.8% (2,5 L) Thermo Scientific 114 2 L 91.2 
Glass Cover Slips (100) Fisher Scientific 87.44 20 units 17.48 
   Subtotal 273.38 
  Total Fungible Cost (€) 2505,793 
Personnel Workhours     
Approximate cost per hour: 20€/hr Workhours: 150 hrs 
   Subtotal 3000 
  Total Laboratory Cost (€) 5505.793 
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Annex IV: Glossary of Terms 
 
BMF = Bone Marrow Failure 
CT = Connective Tissue 
DC = Dyskeratosis Congenita 
DMEM = Dubbeco’s Modified Eagle Medium 
DMSO = DiMethyl SulfOxide 
ECM = Extracellular Matrix 
FBS = Fetal Bovine Serum 
GFP = Green Fluorescence Protein 
GGT = Germline Gene Therapy 
GSE = Genetic Suppressor Element 
HIV = Human Immunodeficiency Virus 
HSC = Hematopoietic Stem Cell 
iPSC = Induced Pluripotent Stem Cell 
IRES = Internal Ribosome Entry Site 
LV = LentiVirus 
SC = Stem Cell 
SCNT = Somatic Cell Nuclear Therapy 
SCT = Stem Cell Transplantation 
TERC = TElomerase RNA Component 
TERT = TElomerase Reverse Transcriptase 
